FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds of formula (I):
where: R1 is phenyl, unsubstituted or mono-or disubstituted independently halogen, cyano, C1-6 alkyl, alkoxy, -SO2CH3, -CF3, -C(CH3)2OH, -CH(CH3)OH, -C(CH3)(C(CH3)2)OH, -SO2(CH2)2OH, -NH(SO2CH3), -C(O)CH3, -C(CH2CH3)2OH, -N(CH3)2, -SO2CH(CH3)2, -SO2(CH2)2OCH2CH3, -SO2(CH2)2N(CH3)2, pyrasol or -SO2(CH2)2-morpholinium, 6-member heteroaryl containing 1 N heteroatom, unsubstituted or substituted C1-6 alkyl, alkoxy or -SO2CH3, or 2,3-dihydrobenzo[1,4]dioxine-6-yl; R2 is C1-6 alkyl, 5-6-member heterocycloalkyl, containing 1 heteroatom selected from O, N, or C3-6-cycloalkyl, unsubstituted or substituted (=O); R3 is hydrogen, halogen, acyl group, cyano, C1-6 alkyl, unsubstituted or mono-, di- or three-substituted independently hydroxy, alkoxy, halogen, C1-6 alkyl, cyano, (=O) or -N(CH3)2, -OCH3, -OCH2C(O)N(CH3)2, -O(CH2)2OCH3, -O(CH2)2N(CH3)2, -OCH(CH3)2, -OC(CH3)2CH2OH, -OCH2CH2OH, -OC(CH3)2C(O)OCH2CH3, -OC(CH3)2C(O)OH, -CH2OC(O)CH2N(CH3)2, -NHC(O)CH2N(CH3)2 or -SO2-C1-6 alkyl; connection between C1 and C2 is single or double bond; X1 represents hydrogen, hydroxy, alkoxy or is absent, if the relationship between C1 and C2 is a double bond; and X2 represents hydrogen or is absent, if the relationship between C1 and C2 is double bond, as well as their pharmaceutically acceptable salts.
EFFECT: mentioned compounds and containing them pharmaceutical compositions are effective for treating metabolic diseases and disorders, such as, for example, type II diabetes mellitus.
35 cl, 4 tbl, 141 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRROLOPYRAZINE KINASE INHIBITORS | 2012 |
|
RU2673064C2 |
| BROMODOMAIN INHIBITORS | 2017 |
|
RU2741808C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | 2009 |
|
RU2514937C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| PYRROLO[2,1-f][1,2,4]TRIAZINE COMPOUND, METHOD FOR PRODUCTION AND USE THEREOF | 2013 |
|
RU2589053C1 |
| PYRIDINE DERIVATIVES CONDENSED WITH HETEROCYCLE | 1996 |
|
RU2136683C1 |
